Syra Health Corp. Class A (SYRA) Key Metrics
SYRA valuation today
Trailing 12 months · as of October 22, 2026- Market cap
- $11.8M
- Enterprise value
- $10.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.5 10-yr median 0.4
- Price / book
- 4.7 10-yr median 1.0
- EV / EBITDA
- 68.7
- Dividend yield
- —
- Beta
- 3.37
SYRA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSYRA valuation Price multiples at each fiscal year-end price.
SYRA returns How much profit the business earns on the capital it uses.
SYRA per-share figures Results divided by the shares outstanding at year-end.
SYRA financial health Debt, liquidity and how easily interest is covered.
SYRA efficiency & capital use Working capital cycle and where the cash goes.
SYRA valuation history
SYRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SYRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SYRA price vs earnings per share
SYRA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $1.0M | $3.0M | $5.0M | — | — | — |
| Enterprise value | −$456,385 | $1.0M | $1.9M | — | — | — |
| Price / sales | 0.1 | 0.4 | 0.9 | — | — | — |
| Price / book | 0.5 | 1.0 | 1.2 | — | — | — |
| EV / sales | -0.1 | 0.1 | 0.3 | — | — | — |
| Earnings yield | −88.3% | −125.6% | −59.3% | — | — | — |
| Free cash flow yield | −44.1% | −98.4% | −56.0% | — | — | — |
| Share price at fiscal year-end | $0.09 | $0.41 | $1.02 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.61 | $1.10 | $1.13 | $0.77 | $0.19 | $0.00 |
| Earnings per share | −$0.08 | −$0.52 | −$0.60 | −$0.29 | −$0.00 | −$0.00 |
| Operating cash flow per share | −$0.04 | −$0.40 | −$0.57 | −$0.31 | −$0.01 | — |
| Free cash flow per share | −$0.04 | −$0.41 | −$0.57 | −$0.32 | −$0.01 | — |
| Cash per share | $0.14 | $0.33 | $0.67 | $0.00 | $0.01 | $0.00 |
| Book value per share | $0.18 | $0.40 | $0.82 | $0.10 | −$0.00 | −$0.00 |
| Tangible book value per share | $0.18 | $0.40 | $0.82 | $0.10 | −$0.00 | −$0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 |
| Debt per share | $0.01 | $0.06 | $0.05 | $0.13 | $0.05 | $0.00 |
| Shares outstanding | 11.9M | 7.3M | 4.9M | 7.3M | 7.3M | 6.0M |
| Change in shares outstanding | +63.1% | +48.9% | −33.0% | 0.0% | +21.9% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −36.0% | −109.1% | −124.4% | −602.6% | — | — |
| Return on invested capital (ROIC) | −91.4% | −310.4% | −173.9% | −175.9% | −2.2% | — |
| Return on assets (ROA) | −27.8% | −87.4% | −81.1% | −148.3% | −1.2% | −142.2% |
| Return on tangible assets | −32.3% | −102.2% | −59.7% | −91.3% | −0.6% | −142.2% |
| Free cash flow margin | −6.2% | −36.9% | −50.3% | −42.1% | −6.7% | — |
| Financial health | ||||||
| Total debt | $143,787 | $452,077 | $248,103 | $934,839 | $342,864 | $3,000 |
| Cash & short-term investments | $1.6M | $2.4M | $3.3M | $3,344 | $100,012 | $3,000 |
| Net debt | −$1.5M | −$1.9M | −$3.0M | $931,495 | $242,852 | $0 |
| Debt / equity | 0.07 | 0.16 | 0.06 | 1.32 | — | — |
| Debt / assets | 0.05 | 0.12 | 0.05 | 0.40 | 0.64 | 1.00 |
| Current ratio | 4.06 | 5.46 | 5.25 | 0.92 | 0.84 | 0.42 |
| Quick ratio | 4.06 | 5.46 | 5.25 | 0.89 | 0.89 | 0.42 |
| Interest coverage | -68.1 | -241.3 | -53.8 | -73.2 | — | — |
| Working capital | $2.1M | $2.7M | $3.9M | −$119,602 | −$70,149 | −$4,167 |
| Invested capital | $627,232 | $935,243 | $981,239 | $1.6M | $235,705 | −$4,167 |
| Tangible asset value | $2.1M | $2.9M | $4.0M | $710,098 | −$7,147 | −$4,167 |
| Net current asset value | $2.1M | $2.6M | $3.9M | −$182,801 | −$161,893 | −$4,167 |
| Graham net-net per share | $0.14 | $0.29 | $0.67 | −$0.08 | −$0.03 | −$0.00 |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 0.1% | 0.3% | 2.2% | 0.4% | — |
| Capex / depreciation | 0.01 | 0.18 | 0.31 | 8.17 | 30.38 | 0.00 |
| Stock-based compensation / revenue | 1.4% | 0.7% | 0.6% | 0.1% | 0.0% | — |
| R&D / revenue | 0.9% | 7.3% | 4.4% | — | — | — |
| SG&A / revenue | 45.7% | 59.8% | 72.7% | 55.3% | 29.5% | — |
| Efficiency | ||||||
| Days sales outstanding | 40.4 | 42.6 | 83.7 | 52.9 | 36.5 | — |
| Days of inventory on hand | — | — | 2.1 | 1.0 | -8.0 | — |
| Days payables outstanding | 16.2 | 16.3 | 39.9 | 22.5 | 23.4 | — |
| Cash conversion cycle (days) | 24.2 | 26.4 | 45.9 | 31.4 | 5.1 | — |
| Receivables turnover | 9.04 | 8.56 | 4.36 | 6.90 | 10.00 | — |
| Payables turnover | 22.50 | 22.42 | 9.14 | 16.23 | 15.58 | — |
| Inventory turnover | — | — | 173.98 | 354.51 | — | — |
| Asset turnover | 2.24 | 1.86 | 1.52 | 3.93 | 5.22 | 0.00 |
| Average receivables | $799,600 | $932,572 | $1.3M | $814,162 | $141,066 | $0 |
| Average payables | $210,605 | $282,340 | $449,290 | $280,659 | $62,865 | $0 |
| Average inventory | — | — | $23,604 | $12,852 | −$21,504 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SYRA's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SYRA valuation and financial ratios
Syra Health Corp. Class A earned a return on equity of −36.0% and a return on invested capital of −91.4% in fiscal 2025. It ended the year with $0.1 million of debt and $1.6 million in cash and short-term investments, a net cash position of $1.5 million. The share count rose 98.4% from 6.0M to 11.9M over 5 years.
See the SYRA income statement, the SYRA chart for price history, or the SYRA stock overview for the latest quote and news.
SYRA key metrics FAQ
What is Syra Health Corp. Class A's return on equity?
Syra Health Corp. Class A's return on equity (ROE) was −36.0% in fiscal 2025: net income of -$0.9 million on average shareholders' equity of $2.5 million.
What is Syra Health Corp. Class A's ROIC?
Syra Health Corp. Class A's return on invested capital was −91.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Syra Health Corp. Class A have?
Syra Health Corp. Class A had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
What is Syra Health Corp. Class A's free cash flow yield?
Syra Health Corp. Class A generated -$0.4 million of free cash flow in fiscal 2025, a free cash flow yield of −44.1% on its market value at year-end ($1.0 million).
What is Syra Health Corp. Class A's current ratio?
Syra Health Corp. Class A's current ratio was 4.06 at the end of fiscal 2025: current assets were 4.06 times current liabilities.